Hansoh Pharma Reports 2023 Revenue Exceeding RMB 10 Billion with Innovative Products Accounting for 67.9%
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
March 26,Hansoh Pharma Announces 2023 Annual Results.
Revenue for the Year 2023RMB 10.104 billion, a year-on-year increase of 7.7%；Profit of 3.278 billion yuan, increased by 26.9% year-on-year;Sales revenue from innovative drugs and collaborative products was approximately RMB 6.865 billion, representing a year-over-year increase of 37.1%., accounting for the proportion of total revenue increased from 53.4% in 2022 to67.9%。
Hansoh Pharma 2023 Performance
Source: Hansoh Pharma Announcement
Overview of pharmaceutical revenues across various fields,Antineoplastic DrugsContinue to be the leader,Proportion in Total RevenueExceeded 60%。
Data source: Hansoh Pharma financial report, compiled and charted by Insight
ResearchInvestment of 2.097 billion yuan，Increased by 23.8% year-on-year, accounting for revenue ratioExample 20.8%。*
Data source: Hansoh Pharma financial report, compiled and charted by Insight
With the investment in R&D, Hansoh Pharma has also achieved positive results in the progress of new drug (including improved new drugs, hereinafter the same) projects in recent years.
According to the Insight database, Hansoh Pharma experienced a surge in new drug project filings in 2021.Before 2021, the number of innovative drug project applications remained at 1-3 per year, but in 2021, it surged to 14 innovative drug projects.. Although there was a decline in 2022,2023 YearA small peak begins to appear again,The number of applications rebounded to 10 projects.. AndThe innovative drugs previously laid out are continuously advancing to the later stages.
Distribution of Hansoh Pharma's Innovative Drugs in China
From: Insight Database Web Version(Same as below)
Based on diversified international cutting-edge new drug technology platforms such as siRNA, ADC, and fusion proteins, Hansoh Pharma has heavily stepped into the field.Biopharmaceutical Track, among whichADC particularly stands out。
According to the Insight database, Hansoh Pharma is currentlyA total of 17 biologic new drugs are under development., six products have entered the clinical stage in China, including one approved for marketing, two in Phase II clinical trials, one in Phase I/II clinical trials, one in Phase I clinical trials, and one approved for the clinical stage.In terms of component categories, thisOut of 17 products, 6 are ADCs., and its R&D progress within the pipeline is advanced, making it the primary focus of Hansoh Pharma.
Two ADCs currently in Phase II clinical trials are respectively targetingB7-H3、B7-H4, these two ADCs are relatively advanced in development progress among similar products globally, especially the latter, which is the fastest progressing in its class.It is precisely based on these two ADCs that Hansoh Pharma partnered with GSK twice in 2023.
October,Hansoh Pharma to Pay $85 Million Upfront + Up to $1.485 Billion in Milestone Payments for B7-H4 ADC(HS-20089) Exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) granted to GSK, primarily for developing its potential in gynecological cancers such as ovarian and endometrial cancer.December,Hansoh Pharma to Pay $185 Million Upfront + Up to $1.525 Billion in Milestone Payments for B7-H3 ADC(HS-20093) Exclusive global licensing rights (excluding mainland China, Hong Kong, Macao, and Taiwan regions) granted to GSK.
In addition,TROP2 ADC（HS-20105）Also initiated Phase I/II clinical trials in November last year.
In addition to ADC, HansohFirst Dual-Antibody, namely HS-20117, the EGFR/c-MET bispecific antibody co-developed with Promab, also initiated clinical research in July of last year (Registration No.:CTR20231924/NCT05940116）。
AndThe layout of chemical drugs is more comprehensive, with the layout on the EGFR target being the most eye-catching.
In the field of anti-tumor, the blockbuster new drug that has been launched is notAlmonertinibThis is the first domestically produced third-generation EGFR-TKI in China.
Ameitinib was first approved for marketing in March 2020 as a second-line treatment for EGFR T790M-positive NSCLC and was included in the Class B National Reimbursement Drug List (NRDL) in the same year.In December 2021, Aumolertinib was approved for a new indication as a first-line treatment for NSCLC with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations, significantly expanding the drug's target population, and was included in the 2022 National Reimbursement Drug List.
Currently, according to the Insight database, Aumetinib has been initiated for adjuvant treatment of NSCLC, etc.13 Phase IIIClinical trials will provide a comprehensive and multi-dimensional medication regimen for more NSCLC patients, ranging from early to advanced stages, including perioperative adjuvant therapy, second-line and later-line treatments, to first-line treatment.
Gantt Chart of the Global Project Development Progress of Aumetinib (Phase II and III Clinical Trials)
Although Hansoh Pharma has established a dominant position in China's third-generation EGFR-TKI market, its布局 of EGFR is not limited to this. The company is also developing treatments targeting...EGFR Rare MutationsandFourth-generation EGFR Inhibitors。In October 2021 and January 2022, Phase I/II clinical trials for two other EGFR inhibitors, HS-10376 and HS-10375, were initiated respectively.
In addition to the in-depth layout of EGFR, Hansoh Pharma is also actively promoting the development progress of other new chemical drugs. In June last year, a long-acting polypeptide EPO receptor agonist...PemostatideApproved for marketing;In July of the same year, a new antifungal drugIbrexafungerp Submitted for marketing approval in China, currently under review (Application No.:JXHS2300072）。
Scan the WeChat QR code to add the editor of Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!
Please indicate: Name + Research Direction!
